Finding. Sertraline plus carfilzomib kills T-ALL and PTCL cells that are addicted to endogenous serine/glycine synthesis. The two approved drugs pull cholesterol in opposite directions, collapse mitochondrial respiration, and raise reactive oxygen species. Citrate rescue argues the injury is metabolic, not a generic cytotoxic smash. SSP-inactive tumor cells and healthy blood cells are largely spared. In an aggressive MYCN PTCL mouse, the combination also outperforms sertraline alone and shifts the immune infiltrate.
Why this paper matters
Most T-ALL and PTCL tumors run a hot SSP. That has already made the SSRI sertraline, a SHMT1/2 inhibitor, an attractive repurposing candidate. The problem, stated plainly, is that sertraline monotherapy stalls the cell cycle and does not control disease in vivo. Verstraete, Heylen, Sánchez-Castillo and colleagues therefore asked whether a clinically used proteasome inhibitor could convert arrest into apoptosis without losing the SSP-selective window.
The answer is carfilzomib. The abstract is not a fishing expedition: they map synergy onto cholesterol flux, lipid restriction, mitochondrial respiration, ROS, DNA damage, and a citrate rescue, then take the pair into an immunocompetent MYCN PTCL model. That is a mechanistic combo brief, not a drug-screen dump.
What they actually measured
Drug effects on cycle, proliferation, and apoptosis were read in T-ALL, PTCL, and healthy blood cells. Proteomic, lipidomic, and metabolic profiles on treated T-ALL cells were followed by targeted validation, metabolic rescues, and SHMT knockdown. In vivo they use a MYCN-overexpressing PTCL model and score immune remodeling.
The metabolic geometry is the mitochondrial reason to file this paper. Sertraline rewires SSP-active T-ALL cells toward cholesterol uptake and biosynthesis, and the authors say that phenotype is not copied by other routes of SSP inhibition. Carfilzomib does the opposite: it promotes cholesterol efflux and drops total lipids, further starving the sertraline-primed cell. On top of that nutrient squeeze, the combination impairs mitochondrial respiration and elevates ROS and DNA damage. Citrate supplementation rescues those injuries, which is the cleanest pointer that TCA/respiratory collapse is on the causal path.
The mouse adds two claims worth keeping separate: better therapeutic efficacy than sertraline alone, and an immune microenvironment richer in natural killer T cells, neutrophils, and eosinophils. Association is not requirement. Still, a metabolic kill that is also immunologically noisy is a different object than a quiet cytostatic.
How to read the score
This is a high-eighties mitochondrial therapeutics brief: two licensed drugs, a selectable metabolic state (SSP activity), a respiratory/ROS mechanism with a metabolite rescue, and an in vivo immune-competent model. Confidence is medium. The abstract does not give combination indices, doses, survival curves, or a head-to-head that explains why carfilzomib outruns bortezomib in the narrative. The claim that sertraline’s cholesterol rewiring is unique among SSP interventions is important and still needs the figure, not the sentence.
What to do with it
Track this if you model T-cell-malignancy metabolism, SHMT biology, or proteasome-plus-bioenergetic combinations. Pull the lipidomic and OCR panels. Treat SSP activity as the stratification hypothesis. Do not write a clinical note from this brief. The implication is directional: SSP-active T-cell tumors may be vulnerable to a cholesterol-and-respiration squeeze that neither sertraline nor carfilzomib fully delivers alone.